Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03188263 · ClinicalTrials.gov registry record · NA

Morning Light Treatment to Improve Glucose Metabolism

A NA study of PreDiabetes and Circadian Dysregulation, sponsored by Northwestern University.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT03188263 is a NA study of PreDiabetes and Circadian Dysregulation that has completed, run by Northwestern University. The registered enrollment target is 10 participants, below the 691-participant average among 89 other PreDiabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03188263, a NA study of PreDiabetes and Circadian Dysregulation, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this pilot study is to test a novel head worn light device (Re-Timer®) as an intervention to improve glucose metabolism in people with prediabetes. The hypothesis is that morning light treatment will improve glucose metabolism. This is a pilot study and the data from this project will be used to develop a larger clinical trial.

Interventions

  • OTHER Bright Light
  • OTHER Dim Light

Study Locations (1)

Illinois

  • Northwestern Memorial Hospital - Chicago

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2017-09-05
Est. Completion 2019-12-31
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT03188263

The ClinicalTrials.gov registry entry for NCT03188263 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 691-participant average among 89 other PreDiabetes trials with a reported enrollment target (99% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Bright Light is the first listed.

NCT03188263 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03188263 about?

NCT03188263 is a clinical study titled "Morning Light Treatment to Improve Glucose Metabolism". The primary purpose of this pilot study is to test a novel head worn light device (Re-Timer®) as an intervention to improve glucose metabolism in people with prediabetes. The hypothesis is that morning light treatment will improve glucose metabolism. This is a pilot study and the data from this proj...

What is the current status of trial NCT03188263?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-09-05. Estimated completion is 2019-12-31.

What conditions does trial NCT03188263 study?

This clinical trial studies the following conditions: PreDiabetes, Circadian Dysregulation.

What interventions are being tested in trial NCT03188263?

The interventions under investigation include: Bright Light (OTHER), Dim Light (OTHER).

Who is sponsoring clinical trial NCT03188263?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03188263 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PreDiabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.